Re-evaluation of cellular radiosensitization by 5-fluorouracil: High-dose, pulsed administration is effective and preferable to conventional low-dose, chronic administration

International Journal of Radiation Biology

Volumn 89, Issue 10, 2013, Pages 851-862

  Valdes, Gilmer ^a   Iwamoto, Keisuke S ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

5 FU; Bolus injection (BI); Colorectal carcinoma; Glioblastoma multiforme; Radiosensitization

Indexed keywords

FLUOROURACIL;

ARTICLE; BOLUS INJECTION; CANCER CELL CULTURE; CANCER RADIOTHERAPY; CELL CYCLE ARREST; CELL CYCLE S PHASE; CELL SURVIVAL; CHRONIC DRUG ADMINISTRATION; CLONOGENIC ASSAY; COLON CANCER; CONTROLLED STUDY; DOSE RESPONSE; DRUG ADMINISTRATION; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG EFFICACY; DRUG EXPOSURE; DRUG MEGADOSE; EVALUATION RESEARCH; GLIOBLASTOMA; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; LOW DRUG DOSE; PRIORITY JOURNAL; PULSED ADMINISTRATION; RADIATION DOSE; RADIATION DOSE FRACTIONATION; RADIATION RESPONSE; RADIOSENSITIVITY; RADIOSENSITIZATION; SURVIVAL RATE; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; DOSE FRACTIONATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FLUOROURACIL; HUMANS; RADIATION TOLERANCE; RADIATION-SENSITIZING AGENTS;

EID: 84885100899     PISSN: 09553002     EISSN: 13623095     Source Type: Journal    
DOI: 10.3109/09553002.2013.797620     Document Type: Article

References (56)

1. Aschele C , Guglielmi A , Tixi LM , Bolli E , Mori AM , Lionetto R , Rosso R, Sobrero A . 1995. Adjuvant treatment of colorectal cancer in the elderly . Cancer Control 2 : S36-38 .
2. Boothman DA , Davis TW , Sahijdak WM . 1994. Enhanced expression of thymidine kinase in human cells following ionizing radiation . International Journal of Radiation Oncology Biology Physics 30 : 391-398 .
3. Boothman DA , Meyers M , Fukunaga N , Lee SW . 1993 . Isolation of x-ray-inducible transcripts from radioresistant human melanoma cells . Proceedings of the National Academy of Sciences of the USA 90:7200-7204 .
4. Borner M, Scheithauer W, Twelves C , Maroun J , Wilke H . 2001. Answering patientsneeds: Oral alternatives to intravenous therapy . Oncologist 6 : S12-16 .
5. Borner MM , Schoff ski P , de Wit R, Caponigro F , Comella G , Sulkes A , Greim G , Peters GJ , van der Born K , Wanders J , et al. 2002. Patient preference and pharmacokinetics of oral modulated UFT versus intravenous fl uorouracil and leucovorin: A randomised crossover trial in advanced colorectal cancer . European Journal of Cancer 38 : 349-358 .
6. Bunz F , Hwang PM, Torrance C , Waldman T , Zhang Y , Dillehay L , Williams J , Lengauer C , Kinzler KW, Vogelstein B . 1999. Disruption of p53 in human cancer cells alters the responses to therapeutic agents . Journal of Clinical Investigation 104: 263-269.
7. Byfi eld JE . 1989 . 5-Fluorouracil radiation sensitization-A brief review. Investigational New Drugs 7: 111-116.
8. Byfi eld JE , Calabro-Jones P , Klisak I , Kulhanian F . 1982 . Pharmacologic requirements for obtaining sensitization of human tumor cells in vitro to combined 5-Fluorouracil or ftorafur and X rays . Inter national Journal of Radiation Oncology Biology Physics 8 : 1923-1933.
9. Carlomagno C , Lauria R , De Laurentiis M , Arpino G , Massarelli E , Ferrara C , Milano A , Vernaglia Lombardi A , Costanzo R, Catalano G , et al. 2002. Second-line chemotherapy with a hybrid-alternating regimen of bolus 5FU modulated by methotrexate and infusional 5FU modulated by folinic acid in patients with metastatic colorectal cancer pretreated with 5FU . A phase 2 study . Oncology 63: 219-225 .
10. Chapman TR, Kinsella TJ . 2011. Ribonucleotide reductase inhibitors: A new look at an old target for radiosensitization . Frontiers in Oncology 1 : 56 .
11. Clarkson B , OConnor A , Winston L , Hutchison D . 1964 . Th e physiologic disposition of 5-Fluorouracil and 5-Fluoro-2 ?-deoxyuridine in man . Clinical Pharmacology and Th erapeutics 5: 581-610.
12. Collins JM , Dedrick RL , King FG , Speyer JL , Myers CE . 1980 . Nonlinear pharmacokinetic models for 5-fl uorouracil in man: Intravenous and intraperitoneal routes . Clinical Pharmacology and Th erapeutics 28 : 235-246 .
13. Denehy TR, Eastman R, SanFilippo L , Gregori CA , Breen JL . 1996. Bolus mitomycin C and 5-FU with sequential radiation for poorprognosis locally advanced cervical cancer . Gynecologic Oncology 60 : 64-71 .
14. Einhorn LH . 1989 . Improvements in fl uorouracil chemotherapy? Journal of Clinical Oncology 7 : 1377-1379
15. Radiation response of mammalian cells grown in culture. 1 . Repair of X-ray damage in surviving Chinese hamster cells. Radiatian Research 13: 556-593.
16. Evans RM , Laskin JD , Hakala MT . 1980 . Assessment of growth-limiting events caused by 5-fl uorouracil in mouse cells and in human cells . Cancer Research 40: 4113-4122.
17. Fraile RJ , Baker LH, Buroker TR, Horwitz J , Vaitkevicius VK . 1980. Pharmacokinetics of 5-fl uorouracil administered orally, by rapid intravenous and by slow infusion. Cancer Research 40: 2223-2228.
18. Fukushima M, Fujioka A , Uchida J , Nakagawa F , Takechi T . 2001. Th ymidylate synthase (TS) and ribonucleotide reductase (RNR) may be involved in acquired resistance to 5-fl uorouracil (5-FU) in human cancer xenografts in vivo . European Journal of Cancer and Clinical Oncology 37 : 1681-1687 .
19. Gastrointestinal Tumor Study Group . 1985. Prolongation of the disease-free interval in surgically treated rectal carcinoma . New England Journal of Medicine 312: 1465-1472.
20. Gunderson LL . 1986 . Perineal irradiation for rectal cancer? International Journal of Radiation Oncology Biology Physics 12: 283-284.
21. Gunderson LL , Collins R , Earle JD , Moertel CK , Krook J , Martenson J . 1986 . Adjuvant treatment of rectal cancer: Randomized prospective study of irradiation -/- chemotherapy: A NCCTG study . International Journal of Radiation Oncology Biology Physics 12 : 169 .
22. He Q , Skog S , Welander I , Tribukait B . 2002 . X-irradiation eff ects on thymidine kinase (TK): I . T K 1 and 2 in normal and malignant cells . Cell Proliferation 35:69-81.
23. Heidelberger C , Baumann ME . 1957 . Studies on OPSPA . I. Th e eff ect of several phosphoramides on transplanted tumors. Cancer Research 17 : 277-283 .
24. Heidelberger C , Griesbach L , Montag BJ , Mooren D , Cruz O , Schnitzer RJ , Grunberg E . 1958 . Studies on fl uorinated pyrimidines . II. Eff ects on transplanted tumors. Cancer Research 18 : 305-317 .
25. Herrmann R, Knuth A , Kleeberg U , Middeke H, Korsten FW , Trux FA , Schmieder A , Evers C . 1992 . Sequential methotrexate and 5-fl uorouracil (FU) vs . FU alone in metastatic colorectal cancer. Results of a randomized multicenter trial. Th e Association of Medical Oncology (AIO) of the German Cancer Society. Annals of Oncology 3 : 539-543 .
26. Hiraoka K , Kimura T , Logg CR, Tai CK , Haga K , Lawson GW, Kasahara N . 2007 . Th erapeutic effi cacy of replication-competent retrovirus vector-mediated suicide gene therapy in a multifocal colorectal cancer metastasis model. Cancer Research 67: 5345-5353.
27. Hoff PM , Cassidy J , Schmoll HJ . 2001 . Th e evolution of fl uoropyrimidine therapy: From intravenous to oral . Oncologist 6 : S3-11 .
28. Hoshino S , Yamashita Y , Maekawa T , Shirakusa T . 2005. Eff ects on DNA and RNA after the administration of two diff erent schedules of 5-fl uorouracil in colorectal cancer patients . Cancer Chemotherapy and Pharmacology 56: 648-652.
29. Khil MS , Kim JH, Mullen CA , Kim SH, Freytag SO . 1996. Radiosensitization by 5-fl uorocytosine of human colorectal carcinoma cells in culture transduced with cytosine deaminase gene . Clinical Cancer Research 2: 53-57.
30. Kubota T , Watanabe M, Otani Y , Kitajima M, Fukushiuma M . 2002. Diff erent pathways of 5-fl uorouracil metabolism after continuous venous or bolus injection in patients with colon carcinoma: Possible predictive value of thymidylate synthetase mRNA and ribonucleotide reductase for 5-fl uorouracil sensitivity . Anticancer Research 22: 3537-3540.
31. Lawrence TS , Davis MA , Tang HY , Maybaum J . 1996. Fluorodeoxyuridinemediated cytotoxicity and radiosensitization require S phase progression . International Journal of Radiation Biology 70 : 273-280 .
32. Liu G , Franssen E , Fitch MI , Warner E . 1997 . Patient preferences for oral versus intravenous palliative chemotherapy . Journal of Clinical Oncology 15 : 110-115 .
33. Longley DB, Boyer J , Allen WL , Latif T , Ferguson PR, Maxwell PJ , McDermott U , Lynch M, Harkin DP , Johnston PG . 2002. Th e role of thymidylate synthase induction in modulating p53-regulated gene expression in response to 5-fl uorouracil and antifolates . Cancer Research 62: 2644-2649.
34. Looney WB , Schaff ner JG , Trefi l JS , Kovacs CJ , Hopkins HA . 1976. Solid tumour models for the assessment of diff erent treatment modalities: IV. Th e combined eff ects of radiation and 5-fl uorouracil . British Journal of Cancer 34 : 254-261 .
35. McGinn CJ , Kinsella TJ . 1993. Th e clinical rationale for S-phase radiosensitization in human tumors . Current Problems in Cancer 17 : 273-321 .
36. McGinn CJ , Lawrence TS . 2001. Recent advances in the use of radiosensitizing nucleosides . Seminars in Radiation Oncology 11 : 270-280 .
37. Miller CR, Williams CR, Buchsbaum DJ , Gillespie GY . 2002. Intratumoral 5-fl uorouracil produced by cytosine deaminase/5-fl uorocytosine gene therapy is eff ective for experimental human glioblastomas . Cancer Research 62: 773-780.
38. Moertel CG , Frytak S , Hahn RG , OConnell MJ , Reitemeier RJ , Rubin J , Schutt AJ , Weiland LH , Childs DS , Holbrook MA , et al . 1981 . Th erapy of locally unresectable pancreatic carcinoma: A randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads - 5-fl uorouracil), and high dose radiation - 5-fl uorouracil: Th e Gastrointestinal Tumor Study Group . Cancer 48: 1705-1710.
39. Moertel CG , Childs DS , Reitemeier RJ , Colby MY , Holbrook MA . 1969. Combined 5Fluorouracil and supervoltage radiation therapy of unresectable gastrointestinal cancer . Th e Lancet 2 : 3 .
40. Mori A , Bertoglio S , Guglielmi A , Aschele C , Bolli E , Tixi L , Rosso R , Sobrero A . 1993. Activity of continuous-infusion 5-fl uorouracil in patients with advanced colorectal cancer clinically resistant to bolus 5-fl uorouracil. Cancer Chemotherapy and Pharmacology 33: 179-180 .
41. Mosconi S , Cascinu S , Zaniboni A , Catalano V , Giordani P , Beretta GD , Martignoni G , Pancera G , Baldelli AM, Poletti P , et al. 2000. Th e value of oxaliplatin in combination with continuous infusion -/- bolus 5-fl uorouracil and levo-folinic acid in metastatic colorectal cancer progressing after 5FU-based chemotherapy: A GISCAD (Italian Group for the Study of Digestive Tract) cancer phase II trial . Tumori 86: 465-469 .
42. Nord LD , Martin DS . 1991 . Loss of murine tumor thymidine kinase activity in vivo following 5-fl uorouracil (FUra) treatment by incorporation of FUra into RNA . Biochemical Pharmacology 42 : 2369-2375 .
43. Nord LD , Stolfi RL , Martin DS . 1992 . Biochemical modulation of 5-fl uorouracil with leucovorin or delayed uridine rescue . Correlation of antitumor activity with dosage and FUra incorporation into RNA. Biochemical Pharmacology 43: 2543-2549.
44. OConnell MJ , Martenson JA , Wieand HS , Krook JE, Macdonald JS , Haller DG , Mayer RJ , Gunderson LL , Rich TA . 1994. Improving adjuvant therapy for rectal cancer by combining protractedinfusion fl uorouracil with radiation therapy after curative surgery . New England Journal of Medicine 331: 502-507.
45. Pardee AB . 1989 . G1 events and regulation of cell proliferation . Science 246 : 603-608 .
46. Seifert P , Baker LH, Reed ML , Vaitkevicius VK . 1975. Comparison of continuously infused 5-fl uorouracil with bolus injection in treatment of patients with colorectal adenocarcinoma . Cancer 36 : 123-128 .
47. Smalley SR, Kimler BF , Evans RG . 1991. 5-Fluorouracil modulation of radiosensitivity in cultured human carcinoma cells . Inter national Journal of Radiation Oncology Biology Physics 20: 207-211.
48. Sobrero AF , Aschele C , Bertino JR . 1997. Fluorouracil in colorectal cancer-A tale of two drugs: Implications for biochemical modulation . Journal of Clinical Oncology 15 : 368-381 .
49. Stephens LC , Ang KK , Schultheiss TE, Milas L , Meyn RE . 1991. Apoptosis in irradiated murine tumors . Radiation Research 127: 308-316.
50. Tepper JE , OConnell MJ , Petroni GR , Hollis D , Cooke E , Benson AB 3rd, Cummings B , Gunderson LL , Macdonald JS , Martenson JA . 1997 . Adjuvant postoperative fl uorouracil-modulated chemotherapy combined with pelvic radiation therapy for rectal cancer: Initial results of intergroup 0114 . Journal of Clinical Oncology 15 : 2030-2039 .
51. Trump DL , Egorin MJ , Forrest A , Willson JK , Remick S , Tutsch KD . 1991. Pharmacokinetic and pharmacodynamic analysis of fl uorouracil during 72-hour continuous infusion with and without dipyridamole . Journal of Clinical Oncology 9 : 2027-2035 .
52. Vallerga AK , Zarling DA , Kinsella TJ . 2004. New radiosensitizing regimens, drugs, prodrugs, and candidates . Clinical Advances in Hematology and Oncology 2 : 793-805 .
53. van Groeningen CJ , Pinedo HM, Heddes J , Kok RM, de Jong AP , Wattel E, Peters GJ , Lankelma J . 1988. Pharmacokinetics of 5-fl uorouracil assessed with a sensitive mass spectrometric method in patients on a dose escalation schedule . Cancer Research 48 : 6956-6961 .
54. Wei S , Ageron-Blanc A , Petridis F , Beaumatin J , Bonnet S , Luccioni C . 1999 . Radiation-induced changes in nucleotide metabolism of two colon cancer cell lines with diff erent radiosensitivities . International Journal of Radiation Biology 75 : 1005-1013 .
55. Withers HR , Taylor JM , Maciejewski B . 1988 . Th e hazard of accelerated tumor clonogen repopulation during radiotherapy . Acta Oncologica 27 : 131-146 .
56. Woolley PV , Ayoob MJ , Smith FP , Lokey JL , DeGreen P , Marantz A , Schein PS . 1985 . A controlled trial of the eff ect of 4- hydroxypyrazolopyrimidine (allopurinol) on the toxicity of a single bolus dose of 5-fl uorouracil . Journal of Clinical Oncology 3 : 103-109 .